HIV-1整合酶抑制剂耐药研究进展  

Advances in drug resistance of HIV-1 integrase inhibitors

作　　者：谢小慧 于凤婷 张霞[3] 赵红心[2] 张福杰 XIE Xiaohui;YU Fengting;ZHANG Xia;ZHAO Hongxin;ZHANG Fujie(Ditan Teaching Hospital,Peking University,Beijing 100015,China;Beijing Ditan Hospital,Capital Medical University,Beijing 100015;Medical Laboratory Science,Weifang Medical College,Weifang 261053,Shandong)

机构地区：[1]北京大学地坛医院教学医院,北京100015 [2]首都医科大学附属北京地坛医院,北京100015 [3]山东省潍坊医学院医学检验学系,山东潍坊261053

出　　处：《中国艾滋病性病》2020年第8期900-902,F0003,共4页Chinese Journal of Aids & STD

基　　金：儿童艾滋病适宜治疗和预防策略研究与应用(2018ZX10302-102);北京市医管中心项目(DFL20191802);Supported by John C.Martin Foundation。

摘　　要：在艾滋病病毒(HIV)整个生命周期中,整合酶是病毒复制整合到宿主细胞脱氧核糖核酸(DNA)过程中十分重要的酶。它可以催化病毒的互补DNA整合进入宿主基因组中。由于整合酶抑制剂的高耐药屏障和低毒性,因此以雷替格韦(RAL)为代表的整合酶抑制剂在治疗HIV中十分具有前景。与其他抗HIV药物类似,整合酶抑制剂也不可避免地会出现耐药的情况。本综述主要总结目前关于整合酶抑制剂耐药的研究情况。Integrase is a very important enzyme for virus replication and integration into host cell DNA during the whole life cycle of HIV.It catalyzes the integration of the virus’s cDNA into the host genome.Since there are no integrase functional analogues in human cells,integrase inhibitors represented by RAL have great potential in the treatment of HIV.Like other anti-HIV drugs,integrase inhibitors will inevitably show drug resistance.This review mainly summarizes the current research on integrase inhibitor resistance.

关 键 词：1型艾滋病病毒 整合酶 耐药 基因型耐药检测 

分 类 号：R512.91[医药卫生—内科学] R373.9[医药卫生—临床医学]